What makes the Libre 3 stand out?
The FreeStyle Libre 3 is Abbott's third-generation CGM, and it represents a significant improvement over both the Libre 2 and the original Libre. The key advances:
Best-in-class accuracy. The Libre 3 achieves a MARD of 7.8% — the best published accuracy figure of any CGM on the market, narrowly edging the Dexcom G7's 8.2%.
World's smallest sensor. The Libre 3 sensor is the size of two stacked coins — noticeably smaller than competitors. There's no separate transmitter; the sensor and transmitter are integrated into a single disposable unit.
1-minute reading interval. The Libre 3 sends a reading every minute — five times more frequently than the Dexcom G7's 5-minute interval. In practice this means a smoother glucose curve and earlier trend detection.
15-day wear. The Libre 3 lasts 15 days per sensor, compared to 10 days for the standard Dexcom G7. That's roughly 2 sensors per month vs 3 — a meaningful cost and convenience difference.
Abbott also offers the Libre 3 Plus, a variant with slightly extended connectivity features. In most markets, the standard Libre 3 remains the primary product.
Accuracy — The best available
With a MARD of 7.8%, the FreeStyle Libre 3 has the best clinical accuracy of any CGM currently on the market. This means readings are within 7.8% of a reference blood glucose value on average across all glucose ranges.
The 1-minute reading interval also means the Libre 3 catches glucose trends faster than 5-minute systems. During meals or exercise — when glucose changes rapidly — this extra resolution gives you a more accurate picture of what's happening in real time.
The Libre 3 is factory calibrated and requires no finger-stick calibration during the sensor lifetime. It is cleared by the FDA for treatment decisions without a confirmatory finger stick.
The world's smallest CGM sensor
The Libre 3 sensor is remarkably small. At roughly the footprint of two stacked coins, it's the most discreet CGM available — less visible under clothing and less likely to snag or catch on objects during daily activity.
Application uses Abbott's one-touch auto-applicator. Placement is approved on the back of the upper arm only (unlike the G7, which also approves the abdomen). Insertion is quick and generally painless.
Water resistance: rated for depths up to 1 meter for up to 30 minutes. Showering and light swimming are fine; extended submersion or diving requires caution.
Adhesive performance is generally good across the 15-day wear period. Some users in hot climates or with active lifestyles use aftermarket adhesive patches to extend adhesion — these are widely available and inexpensive.
LibreLink app — cleaner than ever
The FreeStyle Libre 3 uses Abbott's LibreLink app, which has improved significantly with each generation. The current version is clean, reliable, and well-suited for both clinical and everyday use.
Real-time streaming: unlike earlier Libre generations that required a phone scan to get readings, the Libre 3 streams readings continuously via Bluetooth — no scanning required.
Alerts: high and low glucose alerts are fully configurable. The alert system is solid, though slightly less customizable than the Dexcom G7's comprehensive alarm options.
LibreLinkUp: the companion app allows up to 20 followers to receive real-time glucose readings — more than Dexcom's 10-follower limit, and a meaningful advantage for families.
LibreView: the web-based data platform generates clinical reports for sharing with your care team, including Ambulatory Glucose Profile (AGP) reports and time-in-range analysis.
Limitations: the Libre 3 does not support direct Apple Watch display (a Dexcom G7 exclusive as of 2026). Third-party apps like Juggluco enable Watch display for tech-savvy users, but it requires setup effort. Closed-loop AID compatibility is also more limited than Dexcom.
How much does Libre 3 cost?
Without insurance: approximately $130–200 per month for a 2-sensor pack (30-day supply). This is meaningfully cheaper than the Dexcom G7 ($350+/month uninsured) — a significant advantage for patients without comprehensive coverage.
With insurance: coverage has expanded significantly. Most private insurance plans cover Libre 3 for Type 1 patients and for Type 2 patients on insulin. Medicare covers it for all insulin-using diabetes patients. Out-of-pocket cost with coverage is often $0–30/month.
15-day wear efficiency: with 2 sensors per month instead of 3 (as with the 10-day G7), the per-sensor cost advantage compounds — both in dollars and in the inconvenience of sensor changes.
Uninsured: Libre 3 runs approximately $130–200/month vs $350+ for the Dexcom G7. With insurance, both are typically covered at similar low co-pays. The Libre 3's cost advantage is most significant for patients paying out of pocket.
FreeStyle Libre 3 vs Dexcom G7
| Feature | FreeStyle Libre 3 | Dexcom G7 |
|---|---|---|
| MARD accuracy | 7.8% | 8.2% |
| Wear time | 15 days | 10 days (15-day version available) |
| Warmup time | 60 minutes | 30 minutes |
| Reading frequency | Every 1 minute | Every 5 minutes |
| Sensor size | Smallest available | Small |
| Apple Watch display | No (3rd party possible) | Yes (native) |
| Closed-loop AID | Limited | Broad support |
| Followers | Up to 20 | Up to 10 |
| Cost (uninsured) | ~$130–200/month | ~$350/month |
The Libre 3 wins on accuracy, wear time, sensor size, follower capacity, and cost. The G7 wins on Apple Watch support, closed-loop AID compatibility, and alert depth. For most people who don't use a closed-loop insulin system, the Libre 3 is the stronger value proposition.
Who should choose the Libre 3?
- Have Type 2 diabetes and want the best-value prescription CGM
- Don't use a closed-loop AID insulin system
- Want the most accurate readings available
- Prefer fewer sensor changes (15-day vs 10-day)
- Are paying out of pocket and cost matters
- Want to share readings with up to 20 followers
- You use or plan to use a closed-loop AID system
- Apple Watch native display is important to you
- You need the most comprehensive alert system
- You have Type 1 diabetes on intensive insulin therapy
The right CGM depends on your specific diabetes management approach, insurance coverage, and clinical needs. Always discuss device selection with your endocrinologist or diabetes care provider.
FreeStyle Libre 3 full specs
| MARD accuracy | 7.8% |
| Wear time | 15 days |
| Warmup time | 60 minutes |
| Reading interval | Every 1 minute |
| Calibration | Not required (factory calibrated) |
| Water resistance | 1m / 30 minutes |
| Approved ages | 4 years and older |
| Wear sites | Back of upper arm |
| App compatibility | iOS 15+, Android 9+ |
| Follower sharing | Up to 20 (LibreLinkUp) |
| Apple Watch support | No native support |
| Prescription required | Yes |
| FSA/HSA eligible | Yes |